ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Start-ups

Biogen and Merck partner with Skyhawk to drug RNA

by Ryan Cross
July 12, 2019 | APPEARED IN VOLUME 97, ISSUE 28

 

Large drugmakers are getting interested in small molecules that target RNA, and they are turning to Skyhawk Therapeutics for help. The start-up will work with Merck & Co. to develop molecules that modify RNA splicing to treat neurological diseases and cancer. And Biogen is expanding a collaboration in which Skyhawk is developing therapies for neurological disorders, including multiple sclerosis and spinal muscular atrophy. Skyhawk will receive undisclosed immediate and milestone payments from both partners.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment